A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone
Conditions:   Granulosa Cell Ovarian Cancer;   Low Grade Serous Ovarian/ Primary Peritoneal Cancer;   Endometrioid Endometrial Cancer
Interventions:   Drug: Onapristone ER;   Drug: Onapristone ER + Anastrozole
Sponsors:   Memorial Sloan Kettering Cancer Center;   Context Therapeutics
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

July 6, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments